Erythrocyte-incorporated 6-mercaptopurine metabolite levels are not affected by recent drug administration during maintenance therapy for childhood acute lymphoblastic leukemia

Background: Childhood acute lymphoblastic leukemia (ALL) maintenance therapy with oral 6-mercaptopurine (6-MP) and methotrexate prevents leukemic relapse by acting against residual lymphoblasts. Non-adherence to oral maintenance therapy significantly increases ALL relapse risk. The levels of intrace...

Description complète

Détails bibliographiques

Auteurs principaux:	Lauryna Aukstikalne, Ignas Klejus, Maria Thastrup, Tadas Zvirblis, Kjeld Schmiegelow, Goda Elizabeta Vaitkeviciene, Linea Natalie Toksvang
Format:	Artigo
Langue:	Inglês
Publié:	Elsevier 2023-12-01
Collection:	EJC Paediatric Oncology
Sujets:	Leukemia Acute Lymphoblastic Maintenance therapy 6-mercaptopurine Relapse
Accès en ligne:	http://www.sciencedirect.com/science/article/pii/S2772610X23000260
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!